Premium
Antioxidant Status in HIV Mono‐infected and HIV/HCV Co‐infected Drug Users in Miami
Author(s) -
Sales Sabrina,
Duan Rui,
Jayaweera Dushyantha,
Bradwin Gary,
Regev Arie,
Rafie Carlin,
Page John Bryan,
Lai Shenghan,
Rodriguez Patricia,
Phillips J Craig,
Baum Marianna K,
Campa Adriana
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a739
Subject(s) - medicine , viral load , vitamin c , human immunodeficiency virus (hiv) , antioxidant , albumin , vitamin e , hepatitis c , immunology , gastroenterology , chemistry , biochemistry
Objective: To compare the antioxidant status of HIV mono‐infected and HIV/HCV co‐infected drug users. Methods: After consenting, demographic, nutritional, medical and treatment questionnaires were completed and anthropometries taken. Blood was drawn for CD4 cell count, HIV viral load, serum albumin, and plasma vitamin A, E, and zinc. Results: Of the 192 participants, 33.8% were co‐infected with Hepatitis C, 74.21% were males, 77.9% were Black and 64.74 % were on HAART. Mean age was 42 years. Serum albumin was significantly lower in the co‐infected (3.74±0.65 g/dL) than in HIV mono‐infected group (3.94±0.52 g/dL, p=0.038). CD4 count, viral load, or use of HAART was not significantly different among the groups. The HIV/HCV co‐infected had significantly lower plasma antioxidants, including zinc (0.61±0.14 mg/L vs. 0.67±0.15 mg/L, p=0.016), vitamin A (39.5±14.1μg/dL vs. 52.4±16.2μg/dL, p=0.0004) and vitamin E (8.29 ±2.1μg/mL vs. 9.89±4.5μg/mL, p=0.053) than the mono‐infected group, which remained significant after adjusting for age, sex, CD4, viral load and ethnicity. Dietary intake was similar in the two groups. Conclusion: HIV/HCV co‐infected drug users had significantly lower plasma antioxidants than the HIV mono‐infected; these differences could not be attributed to a lower antioxidant intake. Further investigation on the role of antioxidants in HIV/HCV co‐infection is needed. Funded by NIDA